VERY LOW RISK, LOW RISK, OR INTERMEDIATE RISK MDS PER IPSS-R

Clinical trials for VERY LOW RISK, LOW RISK, OR INTERMEDIATE RISK MDS PER IPSS-R explained in plain language.

Never miss a new study

Get alerted when new VERY LOW RISK, LOW RISK, OR INTERMEDIATE RISK MDS PER IPSS-R trials appear

Sign up with your email to follow new studies for VERY LOW RISK, LOW RISK, OR INTERMEDIATE RISK MDS PER IPSS-R, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

Experimental drug aims to free MDS patients from blood transfusions

Disease control Terminated

This study tested an investigational drug called etavopivat to see if it could safely treat anemia in adults with certain types of myelodysplastic syndromes (MDS), a bone marrow disorder. The main goal was to see if the drug could help patients increase their hemoglobin levels an…

Matched conditions: VERY LOW RISK, LOW RISK, OR INTERMEDIATE RISK MDS PER IPSS-R

Phase: PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control

Last updated Apr 02, 2026 14:56 UTC

VERY LOW RISK, LOW RISK, OR INTERMEDIATE RISK MDS PER IPSS-R

Get alerted when new VERY LOW RISK, LOW RISK, OR INTERMEDIATE RISK MDS PER IPSS-R trials appear

Experimental drug aims to free MDS patients from blood transfusions